Search results for: Innovation Policy Prize
Filter search results
Rare Disease Day 2024: Why Do We Care About Rare?
29 February 2024
…the value of gene therapies and to address uncertainty in outcomes. They also explore to what extent those recommendations are being achieved across 11 countries. 2. Incentives: Policy levers to…
Taking STRIDES: The value of diagnostics against AMR
10 June 2025
…policy, HTA, and procurement. Share this: Download publication Addressing a critical gap in AMR policy and evaluation Antimicrobial resistance (AMR) is a global health crisis, projected to cause up to…
A Final MVAC Blueprint—and the Start of an R&D Revolution?
6 February 2020
…available here. (2) Rachel Silverman is a Policy Fellow at the CGD, Kalipso Chalkidou is Director of Global Health Policy and Senior Fellow at the CGD. Citation Chalkidou, K., Garau, M., Silverman, R., and Towse A. (2020)….
The Economics of Health in a Shifting Climate: Insights from the 2023 Annual Lecture
26 September 2023
…need policymakers at the forefront to catalyse the necessary policy changes at a local, national and global level. One of the most compelling quotes shared from the Lancet report states…
Reflections from the Region: Healthcare transformation in the Middle East
18 June 2025
…how HTA can serve broader policy goals: pharmaceutical innovation, equitable access, better patient outcomes. That requires an approach that is sensitive to local context and ambitions—something we at OHE are…
Working Towards a Sustainable, Healthy Market for Vaccines: a Comprehensive Framework to Support Policy Dialogue and Decision-Making
1 September 2021
…sustainable innovation and equitable access to address public health needs. Current frameworks that describe the global vaccines market, however, focus primarily on demand-side activities in low- and lower-middle income countries….
Surgical Research and Development in the NHS – Promotion, Management and Evaluation
1 July 2000
…to health policy, if it is to: • stimulate innovation in new services and ways of delivering existing services, in areas consistent with the needs of the NHS and with…
Mikel Berdud
26 February 2015
…interests are the role of intellectual property rights and other pull/push incentives in fostering pharmaceutical innovation; the regulation of pharmaceutical markets and its impact of access to innovation and R&D…
Value-Based Pricing: OHE Comments
23 March 2011
…continuum of various degrees of innovation. This perspective must underlie any VBP. 4. Discussions must include whether the UK has an obligation to price in a way that encourages innovation,…